Physician profile
Robert Scherr
NPI 1386025559
$8,302.63
in general payments reported to CMS, 2019-2025
33 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,589 · 2020: $1,872 · 2021: $706 · 2022: $382 · 2023: $512 · 2024: $2,022 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,752.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,326.50 | 2019-2025 | Aveir, Gallant |
| Atricure, INC. | $863.49 | 2023-2024 | |
| Pfizer INC. | $847.58 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $386.73 | 2021-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.41 | 2023-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $338.93 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $322.22 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $301.88 | 2021-2025 | Lifevest |
| Astellas Pharma US INC | $255.32 | 2019-2021 | |
| Novo Nordisk INC | $244.15 | 2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $208.50 | 2021-2024 | Primo Mri Dr Surescan |
| Medtronic Vascular, INC. | $177.27 | 2019 | |
| Boston Scientific Corporation | $165.55 | 2021-2023 | Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $146.07 | 2021-2025 | Repatha, Repatha |
| Cardiovascular Systems INC. | $144.88 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $143.05 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $130.16 | 2019 | |
| Scpharmaceuticals INC. | $130.15 | 2024-2025 | |
| Cleerly, INC. | $127.07 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Vifor Pharma, INC. | $124.66 | 2019 | |
| Bridgebio Pharma, INC. | $100.80 | 2025 | Attruby |
| Agepha Pharma Fz LLC | $99.52 | 2025 | Lodoco |
| Merck Sharp & Dohme LLC | $97.39 | 2021-2024 | Verquvo |
| Astrazeneca Pharmaceuticals Lp | $66.21 | 2019-2024 | Farxiga |
| Regeneron Healthcare Solutions, INC. | $42.46 | 2019-2025 | Evkeeza |
| Abiomed | $29.34 | 2023 | Impella |
| Kestra Medical Technology Services, INC. | $20.04 | 2024 | Assure Wcd |
| Esperion Therapeutics, INC. | $19.95 | 2025 | Nexletol |
| Glaxosmithkline, LLC. | $18.75 | 2025 | Shingrix, Arexvy |
| Kiniksa Pharmaceuticals, Ltd. | $18.21 | 2023 | Arcalyst |
| Preventice Services, LLC | $17.80 | 2021 | |
| Heartflow, INC. | $16.77 | 2025 | |
| Inspire Medical Systems, INC. | $15.82 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Scherr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.